Accretion Pharmaceuticals Ltd vs Aptus Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 112.5 as of 07 May 15:30 . The P/E Ratio of Accretion Pharmaceuticals Ltd is 0 as of March 2024 .The P/E Ratio of Aptus Pharma Ltd is 0 as of March 2024 . The Market Cap of Accretion Pharmaceuticals Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Aptus Pharma Ltd is ₹ 0 crore as of March 2024 . The Dividend Payout of Accretion Pharmaceuticals Ltd is 0 % as of March 2024 .The Dividend Payout of Aptus Pharma Ltd is 0 % as of March 2024.

About Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in 2014.
Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

FAQs for the comparison of Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Aptus Pharma Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 125 Cr while Market cap of Aptus Pharma Ltd is 305 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd?

As of May 8, 2026, the Accretion Pharmaceuticals Ltd stock price is INR ₹112.5. On the other hand, Aptus Pharma Ltd stock price is INR ₹445.0.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Aptus Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.